World's Best Scientists 2026 revealed!
Sun Young Rha

Sun Young Rha

D-Index & Metrics

Medicine

D-Index
89
Citations
33495
World Ranking
12572
National Ranking
37

Sun Young Rha publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Sun Young Rha sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 814 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Sun Young Rha D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Sun Young Rha sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Sun Young Rha is affiliated with Yonsei University in South Korea and specializes in the field of Medicine, with significant contributions spanning several subfields including Pulmonary and Respiratory Medicine, Oncology, Surgery, Molecular Biology, and Gastroenterology.

Their research work covers various key topics such as:

  • Gastric Cancer Management and Outcomes
  • Cancer Immunotherapy and Biomarkers
  • Gastrointestinal Tumor Research and Treatment
  • Colorectal Cancer Treatments and Studies
  • Esophageal Cancer Research and Treatment
  • Renal cell carcinoma treatment
  • HER2/EGFR in Cancer Research

Sun Young Rha has published extensively in notable scientific journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • ESMO Open
  • Cancer Research and Treatment

Noteworthy recent papers authored or co-authored by Sun Young Rha are:

  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial, 2023, The Lancet Oncology
  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, 2021, New England Journal of Medicine (lead author Robert J. Motzer)
  • Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer, 2022, New England Journal of Medicine (lead author John H. Strickler)
  • Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial, 2023, The Lancet (lead author Yelena Y. Janjigian)
  • PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer, 2021, Journal of Clinical Oncology (lead author Yoon-Koo Kang)

Their collaborative network includes frequent co-authors such as:

  • Hyun Cheol Chung (71 publications)
  • Do-Youn Oh (55 publications)
  • Woo Sun Kwon (49 publications)
  • Minkyu Jung (42 publications)
  • Hyo Song Kim (41 publications)

Best Publications

  • Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

    Atsushi Ohtsu;Manish A. Shah;Eric Van Cutsem;Sun Young Rha

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

    Niantao Deng;Liang Kee Goh;Hannah Wang;Kakoli Das

  • Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes

    Zhi Jiang Zang;Ioana Cutcutache;Song Ling Poon;Shen Li Zhang

  • Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer

    Keun Seok Lee;Hyun Cheol Chung;Seock Ah Im;Yeon Hee Park

  • Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Carlos H. Barrios;Tae Min Kim;Silvia Falcon

  • Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

    Daniel Y.C. Heng;J. Connor Wells;Brian I. Rini;Benoit Beuselinck

  • Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer

    Chia Huey Ooi;Tatiana Ivanova;Jeanie Wu;Minghui Lee

  • The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

    Jenny J. Ko;Wanling Xie;Nils Kroeger;Jae lyun Lee

  • Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy

    Iain Beehuat Tan;Tatiana Ivanova;Kiat Hon Lim;Chee Wee Ong

  • Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

    Yung Jue Bang;Rui Hua Xu;Keisho Chin;Keun Wook Lee

  • Whole genome analysis for liver metastasis gene signatures in colorectal cancer.

    Dong Hyuk Ki;Hei-Cheul Jeung;Chan Hee Park;Seung Hee Kang

  • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

    Robert John Motzer;Camillo Porta;Nicholas J Vogelzang;Cora N Sternberg

  • Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

    Nils Kroeger;Wanling Xie;Jae Lyn Lee;Georg A. Bjarnason

  • Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

    Rana R. McKay;Nils Kroeger;Nils Kroeger;Wanling Xie;Jae Lyun Lee

  • Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases

    S. H. Cheon;S. Y. Rha;H. C. Jeung;C. K. Im

  • Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group

    Winnie Yeo;Hyun C. Chung;Stephen L. Chan;Ling Z. Wang

  • Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas

    Suling J. Lin;Johann A Gagnon-Bartsch;Iain Beehuat Tan;Sophie Earle

Frequent Co-Authors

Hyun Cheol Chung
Hyun Cheol Chung Yonsei University
Sung Hoon Noh
Sung Hoon Noh Yonsei University
Toni K. Choueiri
Toni K. Choueiri Harvard University
Woo Jin Hyung
Woo Jin Hyung Yonsei University
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Patrick Tan
Patrick Tan Duke NUS Graduate Medical School
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Georg A. Bjarnason
Georg A. Bjarnason Sunnybrook Health Science Centre
Yoon-Koo Kang
Yoon-Koo Kang Asan Medical Center
Christian Kollmannsberger
Christian Kollmannsberger University of British Columbia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The journey to a career in medicine offers several diverse paths, many of which can be accessed or advanced through online programs. Besides the traditional MD, students and working professionals often consider flexible online healthcare degrees to expand their qualifications and career options.

Mental health is an area in high demand. For nurses aiming to specialize further, there are shortest post master's pmhnp online programs available, allowing experienced nurses to quickly become Psychiatric Mental Health Nurse Practitioners.

If your interest leans toward the business or administrative side of healthcare, an accredited health care administration degree online can lead to management opportunities in hospitals, government, or private practice. Many prospective leaders also seek accredited graduate programs, such as the cheapest mha programs online, to gain deeper expertise in managing healthcare organizations.

For those looking to reach the highest levels of clinical practice and leadership, there are also most affordable online dnp programs that allow nurses to achieve a Doctor of Nursing Practice remotely—and often at a lower cost.

Exploring these related online degrees offers more flexibility and new career pathways for those passionate about making a difference in medicine and healthcare.

Best Scientists Citing Sun Young Rha

Trending Scientists

Recently Published Articles